TORONTO, Nov. 14, 2013 /CNW/ - A first-ever public-private partnership between the Centre for Addiction and Mental Health (CAMH) and a leading U.S. biotechnology company will be announced at a news conference on Tuesday, November 19.
The partnership is in the area of personalized medicine in mental illness. It will enable research discoveries from CAMH to be brought into widespread clinical use, to the benefit of patients. Substantial savings to the health care system are also predicted.
In attendance will be senior representatives from the company and CAMH, and patient Larry Meikle, MFA student at the University of King's College.
Details are as follows:
|Date:||Tuesday, November 19, 2013|
|Location:|| Royal Conservatory of Music
273 Bloor St. West
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, and one of the world's leading research centres in its field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit www.camh.net.
SOURCE: Centre for Addiction and Mental Health
For further information:
contact: Michael Torres, CAMH Media Relations, 416.595.6015 or [email protected]